IgG1 monoclonal antibody targeting CD38 on myeloma/plasma cells; mediates ADCC, CDC, ADCP, induces direct apoptosis, and inhibits CD38 ectoenzyme activity.
Humanized IgG1 anti-CD38 monoclonal antibody that binds CD38 on malignant plasma cells, triggers ADCC, CDC, and ADCP, induces direct apoptosis, and inhibits CD38 ectoenzyme activity, resulting in depletion of CD38-expressing cells.
YES
DIRECT
Isatuximab binds CD38 on target cells and mediates Fc-dependent killing (ADCC by NK cells, CDC via complement, ADCP by macrophages) and can induce direct apoptosis of CD38+ cells.
Autologous, gene-modified CD19-directed CAR T-cell therapy metabolically enhanced to improve T-cell fitness, persistence, and antitumor activity.
Autologous T cells engineered to express a CD19-directed chimeric antigen receptor recognize CD19 on malignant B cells, triggering T‑cell activation, in vivo expansion, and cytotoxic killing via perforin/granzyme and cytokine release. Metabolic enhancements are incorporated to improve T‑cell fitness, persistence, and function within the tumor microenvironment, increasing antitumor durability.
YES
DIRECT
CD19-directed CAR T cells recognize CD19 on target cells and kill them via perforin/granzyme-mediated apoptosis and cytokine/Fas–FasL signaling.
A PD-L1–blocking monoclonal antibody immune checkpoint inhibitor that prevents PD-1/PD-L1 interaction to reinvigorate T-cell activity.
Avelumab is a human IgG1 monoclonal antibody that binds PD-L1, blocking its interaction with PD-1 to inhibit PD-1 signaling, thereby restoring T-cell activation and antitumor cytotoxicity; its Fc region can also mediate ADCC against PD-L1-expressing tumor cells.
YES
DIRECT
Avelumab binds PD-L1 on target cells and its IgG1 Fc engages Fcγ receptors on NK cells/macrophages to trigger ADCC (and possibly ADCP), directly killing PD-L1–expressing cells; it also indirectly enhances T‑cell killing via PD‑1/PD‑L1 blockade.
Also known as STRO-002 or Luvelta, this is an antibody-drug conjugate targeting folate receptor-α (FOLR1). It is an IgG1 (SP8166) linked via a cathepsin-cleavable linker to the 3-aminophenyl hemiasterlin cytotoxic payload SC209. After FRα binding and internalization, lysosomal cleavage releases SC209, a tubulin polymerization inhibitor, causing mitotic arrest and tumor cell death.
Anti-FOLR1 IgG1 antibody-drug conjugate. After binding folate receptor-alpha on tumor cells, the ADC is internalized and a cathepsin-cleavable linker is lysosomally cleaved to release SC209 (a 3-aminophenyl hemiasterlin tubulin polymerization inhibitor), causing microtubule disruption, mitotic arrest, and tumor cell death in FOLR1-positive cells.
YES
DIRECT
ADC binds FOLR1 on target cells, is internalized, and lysosomal cleavage releases the SC209 tubulin polymerization inhibitor, disrupting microtubules and causing mitotic arrest and cell death in FOLR1+ cells.
Also known as STRO-002 or Luvelta, this is an antibody-drug conjugate targeting folate receptor-α (FOLR1). It is an IgG1 (SP8166) linked via a cathepsin-cleavable linker to the 3-aminophenyl hemiasterlin cytotoxic payload SC209. After FRα binding and internalization, lysosomal cleavage releases SC209, a tubulin polymerization inhibitor, causing mitotic arrest and tumor cell death.
Anti-FOLR1 IgG1 antibody-drug conjugate. After binding folate receptor-alpha on tumor cells, the ADC is internalized and a cathepsin-cleavable linker is lysosomally cleaved to release SC209 (a 3-aminophenyl hemiasterlin tubulin polymerization inhibitor), causing microtubule disruption, mitotic arrest, and tumor cell death in FOLR1-positive cells.
NO
INDIRECT
The ADC binds FOLR1 (not beta-tubulin), is internalized, and releases SC209, which inhibits beta-tubulin polymerization, causing microtubule disruption, mitotic arrest, and death of FOLR1-positive cells.